Regeneron Pharmaceuticals, Inc. (REGN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
REGN Revenue Growth
Revenue Breakdown (FY 2025)
REGN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
REGN Revenue Analysis (2014–2025)
As of May 7, 2026, Regeneron Pharmaceuticals, Inc. (REGN) generated trailing twelve-month (TTM) revenue of $14.92 billion, reflecting strong growth of +19.0% year-over-year. The most recent quarter (Q1 2026) recorded $3.61 billion in revenue, down 7.2% sequentially.
Looking at the longer-term picture, REGN's 5-year compound annual growth rate (CAGR) stands at +11.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $16.07 billion in 2021.
Revenue diversification analysis shows REGN's business is primarily driven by Collaboration Revenue (51%), Product (44%), and Product and Service, Other (5%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BIIB (+0.4% YoY), VRTX (+10.4% YoY), and INCY (+21.5% YoY), REGN has underperformed the peer group in terms of revenue growth. Compare REGN vs BIIB →
REGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| REGNCurrent | $14.9B | +19.0% | +11.0% | 24.9% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 INCY | $5.1B | +21.5% | +14.0% | 26.1% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% |
REGN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.34B | +1.0% | $12.24B | 85.4% | $3.58B | 24.9% |
| 2024 | $14.20B | +8.3% | $12.23B | 86.1% | $3.99B | 28.1% |
| 2023 | $13.12B | +7.8% | $10.87B | 82.9% | $4.35B | 33.2% |
| 2022 | $12.17B | -24.3% | $10.47B | 86.0% | $5.39B | 44.2% |
| 2021 | $16.07B | +89.1% | $13.35B | 83.1% | $8.95B | 55.7% |
| 2020 | $8.50B | +29.6% | $7.14B | 84.0% | $3.58B | 42.1% |
| 2019 | $6.56B | -2.3% | $5.58B | 85.1% | $2.21B | 33.7% |
| 2018 | $6.71B | +14.3% | $6.13B | 91.3% | $2.53B | 37.8% |
| 2017 | $5.87B | +20.8% | $5.33B | 90.8% | $2.08B | 35.4% |
| 2016 | $4.86B | +18.4% | $4.46B | 91.7% | $1.33B | 27.4% |
Full REGN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See REGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs REGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare REGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonREGN — Frequently Asked Questions
Quick answers to the most common questions about buying REGN stock.
Is REGN's revenue growth accelerating or slowing?
REGN revenue is accelerating at +19.0% year-over-year, exceeding the 5-year CAGR of +11.0%. TTM revenue reached $14.9B. Growth momentum has increased versus prior periods.
What is REGN's long-term revenue growth rate?
Regeneron Pharmaceuticals, Inc.'s 5-year revenue CAGR of +11.0% reflects the sustained expansion pattern. Current YoY growth of +19.0% is above this long-term average.
How is REGN's revenue distributed by segment?
REGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.